Advances in spectral unmixing have yielded direct clinical gains, particularly in identifying rare or dim immune populations such as PD-1 low tumor-infiltrating lymphocytes and CD56 bright NK cells [1,48,81,111]. This evidence concerns the gene NCAM1 and neoplasm.